Regen BioPharma Shares Outstanding History (RGBP)
Regen BioPharma reported 39.4M shares outstanding at the end of fiscal 2025.
View full Regen BioPharma company overviewRegen BioPharma annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | 39.4M | 34.1M | +648.82% |
| 2024 | 2024-09-30 | 5.3M | 1.8M | +49.96% |
| 2023 | 2023-09-30 | 3.5M | 151,500 | +4.52% |
| 2022 | 2022-09-30 | 3.4M | −4.35B | −99.92% |
| 2021 | 2021-09-30 | 4.35B | 2.75B | +171.06% |
| 2020 | 2020-09-30 | 1.61B | 1.42B | +790.11% |
| 2019 | 2019-09-30 | 180.3M | 0 | 0.00% |
| 2018 | 2018-09-30 | 180.3M | 40.6M | +29.07% |
| 2017 | 2017-09-30 | 139.7M | −8,448 | −0.01% |
| 2016 · Sep 30 | 2016-09-30 | 139.7M | 25.0M | +21.75% |
| 2015 | 2015-09-30 | 114.8M | 63.1M | +122.35% |
| 2014 | 2014-09-30 | 51.6M | 0 | 0.00% |
| 2013 | 2013-09-30 | 51.6M | — | — |
Regen BioPharma quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | 1.13B | 1.10B | +3481.04% |
| Q2 2026 | 2026-03-31 | 351.4M | 329.9M | +1530.45% |
| Q1 2026 | 2025-12-31 | 108.1M | 86.5M | +401.30% |
| Q4 2025 | 2025-09-30 | 39.4M | 34.1M | +648.82% |
| Q3 2025 | 2025-06-30 | 31.6M | 27.2M | +621.57% |
| Q2 2025 | 2025-03-31 | 21.6M | 17.4M | +423.86% |
| Q1 2025 | 2024-12-31 | 21.6M | 17.8M | +474.71% |
| Q4 2024 | 2024-09-30 | 5.3M | 1.8M | +49.96% |
| Q3 2024 | 2024-06-30 | 4.4M | 991,712 | +29.33% |
| Q2 2024 | 2024-03-31 | 4.1M | 733,256 | +21.69% |
| Q1 2024 | 2023-12-31 | 3.8M | −50.84B | −99.99% |
| Q4 2023 | 2023-09-30 | 3.5M | 151,500 | +4.52% |
| Q3 2023 | 2023-06-30 | 3.4M | −4.92B | −99.93% |
| Q2 2023 | 2023-03-31 | 3.4M | −4.58B | −99.93% |
| Q1 2023 | 2022-12-31 | 50.85B | 46.28B | +1014.12% |
| Q4 2022 | 2022-09-30 | 3.4M | −4.35B | −99.92% |
| Q3 2022 | 2022-06-30 | 4.92B | 1.14B | +30.15% |
| Q2 2022 | 2022-03-31 | 4.58B | 1.65B | +56.08% |
| Q1 2022 | 2021-12-31 | 4.56B | 2.96B | +184.36% |
| Q4 2021 | 2021-09-30 | 4.35B | 4.17B | +2312.75% |
| Q3 2021 | 2021-06-30 | 3.78B | 3.26B | +629.13% |
| Q2 2021 | 2021-03-31 | 2.93B | 2.56B | +678.13% |
| Q4 2020 | 2020-09-30 | 1.61B | 1.35B | +536.79% |
| Q4 2019 | 2019-09-30 | 180.3M | 0 | 0.00% |
| Q3 2019 | 2019-06-30 | 518.5M | 359.7M | +226.63% |
| Q2 2019 | 2019-03-31 | 377.1M | 225.8M | +149.21% |
| Q1 2019 | 2018-12-31 | 252.0M | 105.9M | +72.42% |
| Q4 2018 | 2018-09-30 | 180.3M | 40.6M | +29.07% |
| Q3 2018 | 2018-06-30 | 158.7M | 20.6M | +14.93% |
| Q2 2018 | 2018-03-31 | 151.3M | 13.2M | +9.57% |
| Q1 2018 | 2017-12-31 | 146.2M | 768,194 | +0.53% |
| Q4 2017 | 2017-09-30 | 139.7M | −8,448 | −0.01% |
| Q3 2017 | 2017-06-30 | 138.1M | 3.6M | +2.65% |
| Q2 2017 | 2017-03-31 | 138.1M | 9.9M | +7.69% |
| Q1 2017 | 2016-12-31 | 145.4M | 30.7M | +26.72% |
| Q4 2016 · Sep 30 | 2016-09-30 | 139.7M | 15.4M | +12.41% |
| Q4 2016 · Jun 30 | 2016-06-30 | 134.5M | 25.2M | +23.09% |
| Q2 2016 | 2016-03-31 | 128.3M | 18.9M | +17.33% |
| Q1 2016 | 2015-12-31 | 114.8M | 62.7M | +120.49% |
| Q4 2015 | 2015-09-30 | 124.3M | 72.4M | +139.44% |
| Q3 2015 | 2015-06-30 | 109.3M | 57.4M | +110.59% |
| Q2 2015 | 2015-03-31 | 109.3M | 57.4M | +110.58% |
| Q1 2015 | 2014-12-31 | 52.0M | 433,917 | +0.84% |
| Q4 2014 | 2014-09-30 | 51.9M | — | — |
| Q3 2014 | 2014-06-30 | 51.9M | — | — |
| Q2 2014 | 2014-03-31 | 51.9M | — | — |
| Q4 2013 | 2013-09-30 | 51.6M | — | — |
Regen BioPharma shares outstanding trends
Over the last five reported fiscal years, Regen BioPharma's shares outstanding moved from 1.61B to 39.4M, a change of −1.57B. The latest reported quarter, Q3 2026, shows 1.13B.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regen BioPharma filings at SEC.gov ↗